2020-08-17Announcement: Dr. Alan D’Andrea Joined Scientific Advisory Board of IMPACT Therapeutics
IMPACT Therapeutics announced that Dr. Alan D'Andrea joined Scientific Advisory Board of the company.
2020-08-07IMPACT Announced Dosing of the First Patient in Senaparib and Temozolomide Combination Study
IMPACT Therapeutics announced that the first patient was dosed recently in the combination study of its PARP inhibitor senaparib (IMP4297) and temozolomide (TMZ). This study is a Phase I, open-label, multi-center, dose escalation and expansion study to ev
2020-01-13IMPACT Announced First-Patient-In of its PARP inhibitor IMP4297 in Phase 3 Study
IMPACT Therapeutics announced the phase 3 study of its PARP inhibitor IMP4297 had the first patient dosed recently. This study is a randomized, placebo-controlled, double-blinded, multi-center, phase 3 clinical study in China to evaluate the efficacy and
2020-01-13Announcement: Dr. Chih-Yi Hsieh was appointed as Chief Medical Officer of IMPACT Therapeutics
IMPACT Therapeutics announced that Dr. Chih-Yi Hsieh was appointed as Senior Vice President and Chief Medical Officer, being responsible for global clinical strategy and development of its pipeline products.
2019-11-01IMPACT Announced First-Patient-In of its PARP inhibitor IMP4297 Pivotal Study
IMPACT Therapeutics announced the pivotal clinical study of its PARP inhibitor IMP4297 had the first patient dosed recently. IMP4297 is a new chemical entity targeting PARP developed by IMPACT.
2019-09-12IMPACT Selected to Present at 2019 BioCentury NewsMakers Conference
IMPACT Therapeutics Inc. (“IMPACT”) was selected to present at BioCentury NewsMakers Conference on September 6th, 2019 in New York City. Dr. Jun Bao
2019-01-04Announcement: Bao Jun was appointed as the President & CEO of IMPACT Therapeutics, Inc.
The appointment was effective on Oct.01, 2018. The appointment will help the development of IMPACT Therapeutics, Inc. in China as well as globally. This is a strategic step taken by the Company.
2018-08-03IMPACT Therapeutics Raises $30 Million In Series C Financing
NANJING, China, Aug. 3, 2018 /PRNewswire/ -- IMPACT Therapeutics, Inc. (IMPACT), a China-based clinical-stage biopharmaceutical company dedicated to the discovery and development of "best-in-class" medicine for the treatment of cancer and othe
2017-05-09IMPACT Received IMP4297 Chinese IND Approval
IMPACT Therapeutics, Inc.（(IMPACT) announced that CFDA granted approval to its IND application of IMP4297, a potential best-in-class PARP inhibitor, in January 2017. The company dosed the first patient in its Australian Phase I trial in February 2017 and
2016-02-18IMPACT Therapeutics is pleased to announce the closing of a round of VC financing.
In Dec. 2015 IMPACT Therapeutics, a company dedicated to discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening disease, announced the completion of around $10 million series B fi